SynthesisPloS one2012
Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies.
Synthesis in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Landscape of Genetic Mutations in Appendiceal Cancers.Cancers · 2023Review
- TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.NPJ breast cancer · 2022Review
- Transforming growth factor-β in tumour development.Frontiers in molecular biosciences · 2022Review
- Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.Cancers · 2021Article
- Role and clinical significance of TGF‑β1 and TGF‑βR1 in malignant tumors (Review).International journal of molecular medicine · 2021Review
- Association ofCancers · 2020Article
- Peripheral blood transcriptome identifies high-risk benign and malignant breast lesions.PloS one · 2020Article
- Novel Association of a FamilialThe Korean journal of thoracic and cardiovascular surgery · 2019Article
- A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer risk.Journal of gastroenterology · 2019Article
- TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells.Oncology letters · 2018Article
- Driver gene classification reveals a substantial overrepresentation of tumor suppressors among very large chromatin-regulating proteins.Scientific reports · 2016Article
- Human ortholog of Drosophila Melted impedes SMAD2 release from TGF-β receptor I to inhibit TGF-β signaling.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Single-nucleotide polymorphisms of TGFβ1 and ATM associated with radiation-induced pneumonitis: a prospective cohort study of thoracic cancer patients in China.International journal of clinical and experimental medicine · 2015Article
- Article
- TGFBR1 and cancer susceptibility.Transactions of the American Clinical and Climatological Association · 2014Review
- Associations between genetic variants in the TGF-β signaling pathway and breast cancer risk among Hispanic and non-Hispanic white women.Breast cancer research and treatment · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous epidemiological studies have evaluated the association between TGFBR1 polymorphisms and the risk of cancer, however, the results remain inconclusive. To derive a more precise estimation of the relation, we conducted a comprehensive meta-analysis of all available case-control studies relating the TGFBR1*6A and IVS7+24G>A polymorphisms of the TGFBR1 gene to the risk of cancer.
methodsEligible studies were identified by search of electronic databases. Overall and subgroup analyses were performed. Odds ratio (OR) and 95% confidence interval (CI) were applied to assess the associations between TGFBR1*6A and IVS7+24G>A polymorphisms and cancer risk.
resultsA total of 35 studies were identified, 32 with 19,767 cases and 18,516 controls for TGFBR1*6A polymorphism and 12 with 4,195 cases and 4,383 controls for IVS7+24G>A polymorphism. For TGFBR1*6A, significantly elevated cancer risk was found in all genetic models (dominant OR = 1.11, 95% CI = 1.04~1.18; recessive: OR = 1.36, 95% CI = 1.11~1.66; additive: OR = 1.13, 95% CI = 1.05~1.20). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian and breast cancer. For IVS7+24G>A, significant correlation with overall cancer risk (dominant: OR = 1.39, 95% CI = 1.15~1.67; recessive: OR = 2.23, 95% CI = 1.26~3.92; additive: OR = 1.43, 95% CI = 1.14~1.80) was found, especially in Asian population. In the subgroup analysis stratified by cancer type, significant association was found in breast and colorectal cancer.
conclusionsOur investigations demonstrate that TGFBR1*6A and IVS7+24G>A polymorphisms of TGFBR1 are associated with the susceptibility of cancer, and further functional research should be performed to explain the inconsistent results in different ethnicities and cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.